Masayoshi Miyawaki

<i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancer

Toshiyuki Hirano, Hiroyuki Yasuda, Tetsuo Tani et al. · Oncotarget · 2015 · 158 citations · Full text

Medicine, Oncology, Pharmacology +13

DOCK2 is involved in the host genetics and biology of severe COVID-19

Ho Namkoong, Ryuya Edahiro, Tomomi Takano et al. · Nature · 2022 · 97 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer

Masayoshi Miyawaki, Hiroyuki Yasuda, Tetsuo Tani et al. · Molecular Cancer Research · 2016 · 72 citations · Full text

Medicine, Oncology, Pharmacology +17

Single-cell analyses and host genetics highlight the role of innate immune cells in COVID-19 severity

Ryuya Edahiro, Yuya Shirai, Yusuke Takeshima et al. · Nature Genetics · 2023 · 69 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in <i>ALK</i> -Translocated Lung Cancer Cells

Tetsuo Tani, Hiroyuki Yasuda, Junko Hamamoto et al. · Molecular Cancer Therapeutics · 2015 · 63 citations · Full text

Medicine, Oncology, Pharmacology +16